1. Roehrbom CG (2016) Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology and natural history. In: McDougal WS, Wein AJ, Kavoussi LR, Partin AW, Peters CA (eds) Campbell-walsh urology, 11th edn. Elsevier, Philadelphia, pp 2425–2462
2. Foster HE, Barry MJ, Gandhi MC et al (2018−2019) Benign prostatic hyperplasia: surgical management of benign prostatic hyperplasia/lower urinary tract symptoms. American Urological Association. https://auanet.org/guidelines/benign-prostatic-hyperplasia/lower-urinary-tract-symptoms. Accessed 10 Feb 2020
3. Gravas S, Cornu JN, Gacci M et al (2019) Management of non-neurogenic male LUTS. European Association of Urology. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts. Accessed 10 Feb 2020
4. Siami P, Roehrborn CG, Barkin J et al (2007) Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 28:770–779. https://doi.org/10.1016/j.cct.2007.07.008
5. Siami P, Roehrborn CG, Barkin J et al (2012) In: Smith JA Jr, Howards SS, Preminger GM Hinman’s atlas of urologic surgery, 3rd edn. Elsevier, Philadelphia, pp 451–458